Skip to main content
Premium Trial:

Request an Annual Quote

New Products: BioTheranostics' BioT3 Cancer Test; Natera's Expanded Panorama

Premium

BioTheranostics has launched its BioT3 Metastatic Cancer Solution, a suite of genomics-based tests for metastatic cancer. The tests include CancerType ID for molecular classification of tumors; CancerTarget ID to identify actionable biomarkers associated with on-label targeted therapies; and CancerTreatment ID, which uses next-gen sequencing along with immunohistochemistry and fluorescent in situ hybridization to analyze around 50 cancer-related genes.


Natera has expanded its prenatal fetal aneuploidy test, Panorama, to include screening for five microdeletion syndromes. The expanded test will be available on March 1. DiGeorge syndrome, or 22q11.2 deletion syndrome, will be added as a standard option along with trisomies 21, 18, and 13; triploidy 13; and sex chromosome aneuploidies. Customers will also have the option to add screening for 1p36 deletion, Angelman, Cri-du-chat, and Prader-Willi syndromes.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.